• Autoregulation and chemical vasomotor control of cerebral blood flow (CBF) were measured in 14 patients with cerebral ischemia and infarction classified according to severity and anatomical location before and after intracarotid injection of the beta-adrenergic blocking agent, propranolol hydrochloride (PPL). Intracarotid injection of 1.45 ^g per kilogram body weight per minute of PPL (average total dose 2 mg) was followed by a reduction in CBF and oxygen consumption and an increase of cerebrovascular resistance. Mean arterial blood pressure, intracranial venous pressure, and cerebrospinal fluid pressure were unchanged. Cerebral autoregulation was tested by raising and lowering cerebral perfusion pressure (CPP) by the use of a tilt-table. Chemical vasomotor control of CBF was tested by inhalation of 7% CO 2 + air and voluntary hyperventilation. Following the injection of PPL, cerebrovascular resistance was significantly increased when autoregulation was tested by raising CPP. The autoregulation index decreased significantly during the head-down position and tended to increase during the head-up position, but the latter trend did not reach the level of statistical significance. The chemical regulation index was not altered by propranolol during changes of Pa co ,.
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These results support the view that beta-adrenergic innervation influences cerebral metabolism as well as exerting a tonic cerebral vasodilator tonus. Hence, intracarotid injection of PPL blocks the beta-adrenergic dilator tonus and CBF and oxidative metabolism decrease. Likewise, the ability of cerebral vessels to constrict is improved when CPP is increased since cerebral vasoconstrictor tonus is enhanced. When CPP is lowered, cerebral autoregulation is unchanged or worsens. Chemical regulation of CBF to changes in Pac 0 , is unchanged by beta blockade. • Although it is well known that cerebral vessels are supplied by adrenergic and cholinergic nerves, the extent to which these nerves may influence control of cerebral circulation has yet to be established. 1 " 4 Some investigators 6 " 7 suggested that the autonomic nervous system maintains a vasomotor tonus that may have modifying effects on mechanisms responsible for cerebral autoregulation and CO 2 responsiveness. However, others 8 " 10 have found little or no evidence for any autonomic control of cerebral blood flow (CBF).
The present report is part of a detailed investigation of the possible role of the autonomic nervous system in autoregulation and vasomotor responsiveness as well as cerebral metabolism presently being undertaken. 11 - 12 The present investigation was designed to study any vasomotor effect of betaadrenergic blockade with propranolol (PPL) on autoregulation and chemical regulation of CBF in patients with acute stroke.
Methods

CLINICAL CASE MATERIAL
Fourteen patients were studied with acute cerebral ischemia classified according to location and severity on the basis of neurological, angiographical, EEG, CSF and brain scan findings. Table 1 summarizes the clinical data in relation to age, sex, diagnosis, grade of severity of the neurological deficit, and the interval of time between the ischemic episode and the time of the study. There were nine males and five females ranging in age from 27 to 72 years, with a mean age of 56.9 years. Thirteen patients had cerebral hemispheric in -12  21  21  19  14  X7  6  20  7  20  14  7  11  10   2  4  3  3  2  2  2  3  2  3  2  4 farction; one patient had brain stem ischemia. All patients were arbitrarily classified into four grades 13 according to severity of neurological deficit and clinical course. There were six patients who were grade 2 (reversible ischemic neurological deficit), five grade 3 (presumed cerebral infarction with moderate residual disability), and three grade 4 (presumed cerebral infarction with severe neurological deficit). The interval of time between the cerebral ischemic episode and test measurements ranged from 6 to 21 days, with a mean of 14.2 days.
METHODS FOR SELECTION OF PATIENTS AND OBTAINING INFORMED CONSENT
Suitable patients were selected for admission to the study by two or more of the staff neurologists after review of the patients' records and exclusion of cases where there was some medical contraindication to the procedure. Each patient was seen in consultation by a cardiologist and was not admitted to the study unless he indicated in the record that there was no cardiological or general medical contraindication to the procedure. The procedure was described to the patient or the responsible relative on two separate occasions, first by two members of the neurological staff and second by a specially trained nurse who later witnessed the signing of a standard consent form. The consent form described in writing how the catheters were placed, mentioned possible risks involved, and stated that any further explanation would be provided on request and that the patient might withdraw from the procedure at any time.
PREMEDICATION AND PLACEMENT OF CATHETERS
Each patient was given 50 mg of meperidine hydrochloride intramuscularly before catheterization. Under local anesthesia and fluoroscopic control, a 100 cm No. 8 Lehman cardiac catheter was inserted into an antecubital vein and advanced into the confluence of sinuses to permit free aspiration of blood. In the other arm a 105 cm radiopaque No. 14 catheter, to be used for measurement of central venous pressure, was inserted via the basilar vein into the superior vena cava.
An indwelling Teflon catheter was inserted into both brachial arteries. Two other venous catheters were used for venous infusion and venous return from the extracorporeal system. With the patient in the lateral position, a 17-gauge needle was advanced into the lumbar subarachnoid space and a polyethylene catheter (ID = 0.5 mm) introduced for monitoring CSF pressure. The patient was then returned to the dorsal decubitus position. Arterial blood pressure was monitored by a Statham strain gauge connected to the arterial catheter. The strain gauge sensor was mounted on the tilt-table at the level of the external ear in order to record the effective arterial blood pressure (effective BP) at the brain when the patient's position was altered. Intracranial venous pressure (ICVP) also was monitored at the level of the external ear by the strain gauge connected to the venous catheter whose tip lay in the torcular. Cerebrospinal fluid pressure was monitored by directing a catheter in a cephalad direction into the subarachnoid space with its strain gauge mounted at the level of the cisterna magna. Central venous pressure was recorded with the baseline adjusted at the level of the right atrium.
MEASUREMENT OF CEREBRAL BLOOD FLOW AND METABOLISM
By means of a peristaltic pump, blood was drawn at a constant rate from the right brachial artery and the confluence of sinuses. Arterial and cerebral venous blood were propelled through cuvettes containing electrodes and sensors to measure oxygen tension (Po,), carbon dioxide tension (Pco,). pH and oxygen saturation (S Ol ). The blood was returned to the circulatory system by means of an indwelling catheter in the antecubital vein. Each parameter was recorded on a polygraph.
Arterial and cerebral venous blood glucose were monitored continuously with the Technicon Auto Analyzer. CMR glucose was calculated as the product of CBF and the
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cerebral arteriovenous blood content differences. The oxygen content of arterial and cerebral venous blood was calculated from measurements of oxyhemoglobin (IL 182 co-oximeter) and P 02 (electrode). The electroencephalogram (EEG) and electrocardiogram (EKG) were monitored and recorded during the study. A solution of 2 mg of propranolol (PPL) hydrochloride (Inderal®) diluted in 20 ml of normal saline was slowly injected into the carotid artery on the side of the hemispheric infarction or into the right carotid artery in cases of brain stem ischemia at a rate of 1.45 ng per kilogram body weight per minute over a 15 to 20-minute interval.
To measure cerebral blood flow, a 10 ml bolus of hydrogen-saturated saline was injected into the carotid artery. CBF was calculated from the clearance curve for hydrogen obtained from the confluence of sinuses. Measurement of CBF was performed three times: before propranolol (control), about 15 minutes after completion of the injection of propranolol (measurement No. 1), and 70 minutes after completion of the injection (measurement No. 2). Cerebral oxygen consumption (CMRO 2 ) was calculated as the product of CBF and arteriovenous oxygen content differences [(A-V) O 2 ]. After measuring CBF, any changes in cerebral blood flow induced by body tilting, by inhalation of 1% CO 2 in air, and by voluntary hyperventilation were calculated from (A-V) O 2 differences, since CMRO 2 has been shown to be constant during these procedures.
The mean pressures for arterial, central venous, intracranial and cerebrospinal fluid pressures were calculated in each case by adding one-third of the pulse pressure to the diastolic pressure. Cerebrovascular resistance was calculated from CBF and cerebral perfusion pressure (CPP).
ESTIMATION OF AUTOREGULATION AND CHEMICAL VASOMOTOR INDICES
Quantitative analysis of the impairment of cerebral autoregulation and chemical vasomotor reactivity was based on the following formulae from which may be calculated what we term the autoregulation index (AI) and the chemical regulation index (CI):
where ACBF means the change of cerebral blood flow when ACPP changed from the steady state in the horizontal position to the head-up or head-down positions. Likewise, APa co , means the change from steady state level to hypercapnic or hypocapnic levels during CO 2 inhalation or hyperventilation. In normal individuals with cerebral autoregulation intact, the caliber of cerebral vessels adjusts to maintain CBF constant during changes in perfusion pressure of as much as 180 to 200 mm Hg. Thus, when autoregulation is intact, AI should be zero or close to zero, and any deviation of AI from zero in a plus or minus direction will be in direct proportion to the degree of dysautoregulation. CI is reportedly greater than unity under normal conditions. Any deviation below unity indicates impaired CO 2 reactivity or impaired chemical regulation.
The significance of difference for all mean values was tested by Student's t test for paired data, assuming P < 0.05 to be statistically significant. The results are presented as mean values with standard deviation. 
Cerebral blood flow (CBF) and cerebral oxygen consumption (CMROil decreased significantly 15 minutes after completion of the injection of propranolol (measurement No. I), and 70 minutes after the completion of the injection (measurement No. 2). Cerebro vascular resistance (CVR) changes paralleled the changes in CBF. as might be expected under constant cerebral perfusion pressure.
Results
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Cerebral blood flow decreased significantly from 34.2 to 31.5 ml/100 gm per minute immediately after completion of the injection and to 31.3 ml/100 gm per minute 70 minutes after injection of propranolol. The decrease in CBF was 8.5% and 8.1% of control values (table 2, fig. 1 ) and occurred without any significant change in Pa C02 -Cerebrovascular resistance increased significantly on both occasions after injection of PPL from 2.88 to 3.22 and 3.14 mm Hg per ml/100 gm per minute, respectively, 11.3% and 8.7% increases over the control values, indicating cerebral vasoconstriction. CMRO 2 decreased significantly from 2.44 prior to injection of PPL to 2.19 and 2.30 ml/100 gm per minute following propranolol injection, which is a decrease of 8.6% and 5.4% of control values. It can be seen from figure 1 that the change in CBF parallels the reduction in CMRO 2 . Hence, propranolol did not alter the cerebral arteriovenous oxygen content in confirmation of the observation previously reported by Fujishima et al. Cerebral glucose consumption likewise decreased from 3.00 to 2.45 and 2.52 mg/100 gm per minute after injection of propranolol. ml/100 gm/min/mm Hg PPL = Propranolol.
• = Statistically significant as compared with steady state values (P < 0.01). The induced responses in arterial blood pressure, intracranial venous pressure, CSF pressure, and blood gases during hypotension produced by the head-up tilt position were not significantly altered by propranolol injection (table 4) . CBF decreased slightly more during the head-up position after PPL with the increased CVR, but this decrease was not significant. Likewise, the autoregulation index (AI) increased from 0.187 to 0.284 after PPL infusion, but the change did not reach the level of statistical significance (table 3, fig. 2 ).
During the head-down position (table 5) , CBF increased by 2.2 ml/100 gm per minute (from 34.2 to 36.4) before PPL. After injection of PPL, the increment of CBF during the increase in CPP was significantly reduced to 0.4 ml/100 gm per minute (from 31.6 to 32.0). Likewise, the increase in CVR with head-down tilting after PPL was significantly greater than before PPL, indicating improved autoregulation. The autoregulation index (AI) decreased significantly during hypertension from 0.310 to 0.074 after injection of propranolol (table 3, fig. 2 ). Paradoxical autoregulation (negative AI) was shown in three cases (Case Nos. 5, 7 and 9). In these cases there was an increase of CBF when CPP was decreased or a reduction of CBF when CPP was raised. Such paradoxical responses during hypercapnia have been shown experimentally to be associated with cerebral edema and pressure effects. 15 The chemical regulation index (CI) during 7% CO 2 inhalation and hyperventilation were unchanged by PPL injection (tables 3, 6, and 7, fig. 3 ).
During tilting, cerebral perfusion pressure did not decrease below the known autoregulatory range (60 mm Hg) and arterial P CO j was not altered significantly in any of the patients. Patients who showed either conspicuous changes in arterial blood pressure or marked changes in arterial P COj (over 60 mm Hg or below 20 mm Hg) during induced hypercapnia or hypocapnia were excluded, since most patients had impaired cerebral autoregulation and even in normal subjects cerebral vasomotor capacitance may be influenced by abnormally high or low levels of arterial P co ,- 
EFFECT
Effect of PPL on chemical vasomotor capacitance: No significant change after the infusion was observed in CI during either induced hypercapnia or hypocapnia. Closed circles indicate individual values and open circles indicate mean values with standard deviations.
Discussion THE EFFECT OF PROPRANOLOL O N CEREBRAL CIRCULATION A N D METABOLISM I N STROKE
It has been reported previously that propranolol reduces CBF, CMRO 2 and CMR glucose in dogs. 14 '
16
The present study confirms these observations in patients with stroke. Fujishima et al. 14 concluded that propranolol exerts a primary effect on brain metabolism, leading to a consequent reduction of CBF as cerebral CO 2 production is reduced. Whitsitt and Lucchesi" observed that both 1-propranolol and dpropranolol (the latter being a dextroisomer without known beta-blocking activity) produced an increase in coronary vascular resistance and attributed this effect to the negative ionotropic effect of propranolol or some other nonspecific action unrelated to betaadrenergic blockade. The effects of propranolol on central nervous mechanisms have been reviewed 18 and it seems probable that these central effects are dependent on the drug's beta-blocking activity although this is still unproved. In the present study, propranolol resulted in a rapid reduction of CBF, CMRO 2 and CMR glucose in patients with stroke presumably by rapidly crossing the blood-brain barrier. The CBF decreased by 8.5% immediately after the intracarotid injection of 2 mg propranolol and this persisted for approximately 70 minutes after injection. The changes in CBF paralleled changes in CMRO 2 , CMR glucose and, as might be expected from the mathematical formula used to derive it, cerebrovascular resistance ( fig. 1) . The increase in cerebrovascular resistance must have resulted, in part, from a reduction in cerebral glucose and oxygen consumption and CO 2 production. Despite the reduction in CBF, the P 02 and P c02 of cerebral venous blood was unaltered by propranolol before PPL after PPL 
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partly because of assumed reduction in cerebral oxidative metabolism.
Norepinephrine is known to stimulate glucose and oxygen consumption by the brain and there is evidence that this effect is diminished by PPL. Following the administration of propranolol, a significant reduction of CMR glucose was observed despite an increase in glucose levels in both arterial and cerebral venous blood. Estler and Ammon 19 found that propranolol reduces glycolytic metabolism in brain, apparently by direct inhibition of 3'5' cyclic AMP and its influence on the glycolytic enzymes. Since 6 moles of oxygen are required for complete oxidation for every mole of glucose consumed by the brain, it seems reasonable to suppose that propranolol decreases not only glycolytic carbohydrate metabolism by the brain, but thereby also reduces CMRO 2 . This effect may be enhanced in patients with cerebral infarction since norepinephrine is released into infarcted brain tissue and may abnormally stimulate cerebral glucose and oxygen metabolism. Results from the present study indicate that besides reducing cerebral blood flow and increasing cerebrovascular resistance, beta-adrenergic blockade also improves the autoregulation capacity of infarcted brain to tolerate increases of perfusion pressure. There was a tendency, although not statistically significant, to increase the impaired autoregulation when the cerebral perfusion pressure was lowered. Thus, betaadrenergic blockade has pharmacologically the opposite effects on autoregulation than alpha-adrenergic blockade with phenoxybenzamine." Furthermore, beta-adrenergic blockade has no effect on cerebral chemical vasomotor control, similar to the findings previously reported after adrenergic blockade. To show continuous recording of CO 2 Significance* P > 0.1 (NS) P > 0.05 (NS) P < 0.05 P < 0.05 P > 0.05 (NS) P < 0.05 P < 0.05 P > 0.1 (NS) P > 0.1 (NS) P < 0.05 P > 0.1 (NS) P > 0.1 (NS) P < 0.01 P < 0.01 P < 0.01 23 have demonstrated that cerebrovascular reactivity to Paco, is preserved in patients with Shy-Drager syndrome in which the central autonomic nervous system is impaired and autoregulation is lost. These results indicate that the mechanisms responsible for cerebral autoregulation and chemical regulation are independent, the former being influenced by the autonomic nervous system but the latter little or not at all.
inhalation (induced hypercapnia) in Case No. 9: Cerebral venous gases and pH showed excellent response to 7% CO 2 in air inhalation before and after PPL infusion. Arterial blood pressure (BP) remained constant but intracranial pressure (ICP) increased during inhalation. Chemical regulation indices (CI) were 2.54 before and 3.50 after the infusion, indicating normal vasomotor reactivities to induced hypercapnia.
Harper et al. 7 and Stoica et al." postulated a dual control system of CBF wherein the intraparenchymal arterioles are controlled primarily by an intrinsic chemical regulation while the extraparenchymal vascular system is controlled primarily by the sympathetic nervous system. Gotoh et al., 12 likewise, offered evidence for a dual control of the cerebral circulation, observing that arteries with a diameter of more than 50 n are regulated primarily by the autonomic nervous system whereas arteries with a diameter of less than 50 n are regulated more by chemical control. Furthermore, Lowe and Gilboe 28 have demonstrated the presence of alpha-adrenergic and beta-adrenergic receptors in the cerebral vessels of the dog and observed an increase of cerebrovascular resistance following administration of propranolol. The present study plus our earlier studies of the effects of alpha-adrenergic blockade with phenoxybenzamine indicate that in our patients with stroke, there exist alpha and beta receptors in the cerebral vessels which behave similarly to those reported in animal preparations.
Taken together, our findings indicate that when the beta receptors in cerebral vessels are blocked, the vasoconstrictive mechanisms are capable of greater responsiveness to increases in CPP because of the resulting increased action of the alpha receptors on the cerebral vessels. On the other hand, when the alpha receptors are blocked, the vasodilator mechanisms are enhanced and autoregulation is improved when the cerebral perfusion pressure is decreased.
It is concluded that the adrenergic nervous system plays a part in autoregulation of CBF but little or no role in cerebral chemical regulation.
